Sun Pharmaceutical Industries Limited (SUNPHARMA) — Financial Results | 31 January 2025(3 announcements)

Sun Pharmaceutical Industries Limited reported consolidated gross sales of ₹134,369 million for Q3 FY25, up 10.5% YoY, with adjusted net profit rising 24.1% YoY to ₹32,196 million and EBITDA increasing 15.3% YoY to ₹40,090 million (29.3% margin). The company declared an interim dividend of ₹10.50 per share and highlighted growth in India (13.8%), Rest of World (21%), and Global Specialty (17.5%) sales. Strategic moves included a $347.7 million Taro acquisition, a $8.39 million West Virginia settlement, and a 60% stake in Vivaldis Health and Foods. FDA approval of Leqselvi for alopecia areata was noted, though subject to a court injunction. The filing confirms no material misstatements and aligns with SEBI compliance.

Sun Pharmaceutical reported a 32% YoY revenue jump to ₹61.92 crores for Q3 2024, driven by strong profit growth of 69.9% to ₹11.81 crores, with total income rising 20% to ₹62.60 crores and expenses up 17% to ₹49.95 crores. The Board approved results on January 31, 2025, including exceptional items from litigation and restructuring. Net profit for the nine-month period reached ₹22.82 crores, reflecting robust operational performance and strategic acquisitions.

Sun Pharmaceutical reported consolidated net profit of ₹87.22 crores for Q3 FY25, up 32% from ₹65.97 crores in Q3 FY24, driven by strong revenue growth to ₹1,150.5 crores (+15% YoY). The company highlighted improved operational efficiency and cost management as key contributors to profitability.